Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

By M. Shiffman, F. Suter, B. Bacon, D. Nelson, H. Harley, R. Solá, S. Shafran, K. Barange, A. Lin, A. Soman and 1 more. New England Journal of Medicine, 2007

612 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/d38ce59bfee3ee8d85dbca05a64ea15046addc84

Citations in the corpus

• Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (2013, neutral): “Decreased platelet count: 25,000 to <50,000/mm3 2 (3) 0 2 (2) 0”
• Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014, neutral): “Hispanic or Latino 10 (12) 6 (8) 1 (9) 36 (14)”